Created at	Source	Raw Value	Validated value
April 27, 2022, 9:30 a.m.	eu	1. Percentage of participants with COVID-19 (laboratory-confirmed severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] infection with symptoms) through Day 14 2. Percentage of participants with ≥1 adverse event 3. Percentage of participants discontinuing from study therapy due to AE	1. Percentage of participants with COVID-19 (laboratory-confirmed severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] infection with symptoms) through Day 14 2. Percentage of participants with ≥1 adverse event 3. Percentage of participants discontinuing from study therapy due to AE